Corcept Therapeutics and Lilly Continue Collaboration
Posted on: Thursday, 4 September 2008, 12:00 CDT
US-based pharmaceutical company Corcept Therapeutics has announced that Eli Lilly and Company has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzapine induced weight gain.
Corcept has previously published the results of studies in rats that demonstrated that CORLUX, a potent GRII (cortisol) receptor antagonist, both reduced the weight gain associated with the ongoing use of olanzapine and mitigated the weight gain associated with the initiation of treatment with olanzapine.
Joseph Belanoff, CEO of Corcept Therapeutics, said: "While it is not fully understood why the group of medications known as atypical antipsychotic medications, including olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel) and clozapine (Clozaril), are associated with varying degrees of treatment emergent weight gain, hyperglycemia and diabetes mellitus, it is possible that a cortisol receptor antagonist may eventually prove to be useful in patients who need to take these medications.
"Lilly has been vigilant in examining the metabolic changes associated with olanzapine; we are very pleased to continue our work with them and are appreciative of their support."
Source: Datamonitor
Related Articles
- Orexigen Initiates Phase IIa Antipsychotic-Associated Weight Gain Study
- Corcept Therapeutics Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine
- Jonathan Bailey Associates Celebrates Completion of Medical City Children's PICU and CHSU
- J.D. Power and Associates Reports: Crozer-Chester Medical Center Recognized for Providing an Outstanding Outpatient Experience
- Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows
- J.D. Power and Associates Reports: St. Vincent's Medical Center in Jacksonville Recognized for Second Consecutive Year for Providing an Outstanding Inpatient Experience
- A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain
- Corcept Preclinical Trials Show Corlux(R) Prevents Weight Gain Associated With Use of Olanzapine, the Active Ingredient in Zyprexa(R)
- Weight and Receptor Status Predict Breast Cancer Death
- Association of Vitamin D Receptor Gene Polymorphisms With Childhood and Adult Asthma
User Comments (1)
| 1. |
Posted by Daniel Haszard on 09/04/2008, 15:48 Eli Lilly is being sued for fraudulent promotion of it's Zyprexa drug, by the Attorney Generals of over a dozen states |
RSS Feeds